Prospective Evaluation of Immunological, Molecular-genetic, Image-based and Microbial Analyzes to Characterize Tumor Response and Control in Patients With Inoperable Stage III NSCLC Treated With Chemoradiotherapy Followed by Consolidation Therapy With Durvalumab
Clinical trial NCT05027165 · UNKNOWN
Trial details
- NCT number
- NCT05027165
- Sponsor
- LMU Klinikum
- Status
- UNKNOWN
- Study type
- OBSERVATIONAL
- Start date
- 2020-11-07
- Primary completion
- 2024-01-31
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.